Galena Biopharma (NASDAQ:GALE) shares were up 7% today on news that the company had finished enrollment in a phase 2a trial.
While it's great that the company successfully enrolled people in the trial, it's not really an indication of the business' opportunities moving forward like actual trial data is.
In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson suggest three much more important things investors need to watch at Galena.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.